BCM
IFRX icon

BlueCrest Capital Management’s InflaRx IFRX Stock Holding History

BlueCrest Capital Management’s Portfolio IFRX Stock Details IFRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,000
Closed -$567K – 730
2019
Q1 		$567K Buy
+15,000
New +$559K 0.02% 436

Other funds holding IFRX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LI
Leap Investments Chicago, Illinois $152M AUM 3.6% 1-Year Est. Return

BlueCrest Capital Management's IFRX Position: Q2 2019 in Review

BlueCrest Capital Management sold out of InflaRx (IFRX) in Q2 2019, closing a stake of 15,000 shares — an estimated $567K sold.

BlueCrest Capital Management first reported a position in IFRX in Q1 2019 and held it in 1 quarter. The position peaked at $567K in Q1 2019. 28 funds tracked by Wall St. Rank hold IFRX as of Q2 2019.

  • BlueCrest Capital Management reported no remaining InflaRx position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 15,000 InflaRx shares in Q2 2019, an estimated $567K.
  • BlueCrest Capital Management first reported a position in InflaRx in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's InflaRx position peaked at $567K in Q1 2019.
  • 28 funds tracked by Wall St. Rank held InflaRx as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.